ClinicalTrials.Veeva

Menu

Identification of Asymptomatic Patients at Very High Cardiovascular Risk: Contribution of a Strategy Based on Carotid and Coronary Explorations, Compared to Simple Risk Calculation Using the European "SCORE 2" Algorithm. (IDEA-CVR)

E

Elsan

Status

Enrolling

Conditions

Cardiovascular (CV) Risk
Atheroma
Cholesterol
Myocardial Infarction

Treatments

Other: SCORE2

Study type

Observational

Funder types

Other

Identifiers

NCT07252830
IDEA-CVR

Details and patient eligibility

About

To prevent myocardial infarction ( MI), coronary atheroma development by LDL-cholesterol deposition in the arterial wall is the basis. Since atheromatous plaques develop slowly before becoming symptomatic, their early detection in asymptomatic patients and the implementation of an effective strategy to prevent their progression constitute the most promising primary prevention strategy. In younger subjects, the main modifiable pro-atheromatous factors are smoking and an excessively high LDL-C level, partly genetically predetermined, but also favored by a diet too rich in saturated fats and a lack of physical activity. In the French national MI registry, the average age of patients is 62 years (Arch Cardiovasc Dis 2021 Oct;114(10):647-655). Half of MIs therefore occur at working age due to rupture of atheromatous plaques, which had developed during the months/years preceding the acute event.

According to the latest recommendations of the European Society of Cardiology (ESC) on CV prevention published in August 2021, the visualization of coronary or carotid atheromatous plaques justifies considering the patient as having atherosclerotic cardiovascular disease (ASCVD), and automatically places them in the "very high CV risk" category, with an LDL-cholesterol target of <0.55 g/L. However, these recommendations do not clearly define the criteria justifying the use of imaging in asymptomatic patients.

In current practice, CV risk stratification for asymptomatic patients with no prior CV disease is currently based on risk calculation using the European "SCORE 2" algorithm, available online. It allows the calculation of the absolute risk in % of occurrence of a fatal or non-fatal CV event (myocardial infarction, stroke) over 10 years.

The main objective of this study is to describe patients reclassified as "very high CV risk" following the detection of atheroma plaques formed in relation to their risk level estimated by SCORE2.

Full description

It is a national, single-center, retrospective and prospective study on the collection of routine care data.

Enrollment

1,000 estimated patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age > 40 years and < 80 years referred to general cardiology consultation
  • LDL-C level > 1.6 g/L, or LDL-C level > 1.3 g/L with at least one associated major cardiovascular (CV) risk factor (RCF) (smoking, hypertension, diabetes).
  • Coronary artery reserve assessment and EDTSA performed in a day hospital

Exclusion criteria

  • Known or suspected carotid atherosclerotic disease
  • Significant ischemic heart disease known or suspected at the time of the initial consultation
  • Protected adult patient (patient under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision)
  • Opposition expressed by the patient to the use of their health data.
  • Patient may have limited understanding of the information sheet

Trial design

1,000 participants in 1 patient group

Asymptomatic patients, in screening / primary prevention
Treatment:
Other: SCORE2

Trial contacts and locations

1

Loading...

Central trial contact

Aurelia Cassany, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems